Mexico's health regulator COFEPRIS has approved an oral formulation of semaglutide for adults struggling with obesity [1].
The authorization comes as the country attempts to combat a public health crisis characterized by widespread weight-related comorbidities. Providing a pill-based alternative to injectable treatments may increase accessibility for a population with high metabolic risk.
The medication is authorized for use in adults with obesity or those who are overweight and have associated health conditions [1]. It serves as a daily treatment designed to aid in weight reduction.
Public health data indicates a severe need for such interventions in the region. Approximately 75% of Mexican adults are classified as overweight or obese [1]. This statistic means roughly three out of four adults in the country are affected by these conditions [2].
COFEPRIS officials said they approved the oral version to address these prevalence rates [1]. While other GLP-1 drugs have received separate authorizations in different markets, this specific approval focuses on the oral delivery of semaglutide within Mexico.
The rollout of the pill is expected to provide a more convenient option for patients who avoid needles or require a more flexible dosing schedule. By integrating the drug into the national health landscape, officials said they hope to lower the long-term burden of obesity-related diseases.
“Mexico's health regulator COFEPRIS has approved an oral formulation of semaglutide for adults struggling with obesity.”
The approval of an oral semaglutide pill marks a shift toward more accessible pharmacological interventions for obesity in Mexico. By moving away from injectable-only options, the government can potentially scale treatment to a larger portion of the 75% of the adult population currently facing overweight or obesity issues, though the actual impact will depend on the drug's cost and distribution within the public health system.
